1400876-94-9Relevant articles and documents
Discovery of a JAK1/3 Inhibitor and Use of a Prodrug to Demonstrate Efficacy in a Model of Rheumatoid Arthritis
Spergel, Steven H.,Mertzman, Michael E.,Kempson, James,Guo, Junqing,Stachura, Sylwia,Haque, Lauren,Lippy, Jonathan S.,Zhang, Rosemary F.,Galella, Michael,Pitt, Sidney,Shen, Guoxiang,Fura, Aberra,Gillooly, Kathleen,McIntyre, Kim W.,Tang, Vicky,Tokarski, John,Sack, John S.,Khan, Javed,Carter, Percy H.,Barrish, Joel C.,Nadler, Steven G.,Salter-Cid, Luisa M.,Schieven, Gary L.,Wrobleski, Stephen T.,Pitts, William J.
supporting information, p. 306 - 311 (2019/03/19)
The four members of the Janus family of nonreceptor tyrosine kinases play a significant role in immune function. The JAK family kinase inhibitor, tofacitinib 1, has been approved in the United States for use in rheumatoid arthritis (RA) patients. A number